Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes.
Tehranchi R, Invernizzi R, Grandien A, Zhivotovsky B, Fadeel B, Forsblom AM, Travaglino E, Samuelsson J, Hast R, Nilsson L, Cazzola M, Wibom R, Hellström-Lindberg E. Tehranchi R, et al. Among authors: samuelsson j. Blood. 2005 Jul 1;106(1):247-53. doi: 10.1182/blood-2004-12-4649. Epub 2005 Mar 8. Blood. 2005. PMID: 15755901 Free article.
Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.
Hellström-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Nilsson-Ehle H, Samuelsson J, Tangen JM, Winqvist I, Oberg G, Osterborg A, Ost A. Hellström-Lindberg E, et al. Among authors: samuelsson j. Blood. 1998 Jul 1;92(1):68-75. Blood. 1998. PMID: 9639501 Free article. Clinical Trial.
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Oberg G, Porwit-MacDonald A, Rådlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F; Scandinavian MDS Group. Hellström-Lindberg E, et al. Among authors: samuelsson j. Br J Haematol. 2003 Mar;120(6):1037-46. doi: 10.1046/j.1365-2141.2003.04153.x. Br J Haematol. 2003. PMID: 12648074 Free article.
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.
Hast R, Hellström-Lindberg E, Ohm L, Björkholm M, Celsing F, Dahl IM, Dybedal I, Gahrton G, Lindberg G, Lerner R, Linder O, Löfvenberg E, Nilsson-Ehle H, Paul C, Samuelsson J, Tangen JM, Tidefelt U, Turesson I, Wahlin A, Wallvik J, Winquist I, Oberg G, Bernell P. Hast R, et al. Among authors: samuelsson j. Leukemia. 2003 Sep;17(9):1827-33. doi: 10.1038/sj.leu.2403035. Leukemia. 2003. PMID: 12970783 Clinical Trial.
Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations.
Tehranchi R, Fadeel B, Schmidt-Mende J, Forsblom AM, Emanuelsson E, Jadersten M, Christensson B, Hast R, Howe RB, Samuelsson J, Zhivotovsky B, Hellström-Lindberg E. Tehranchi R, et al. Among authors: samuelsson j. Clin Cancer Res. 2005 Sep 1;11(17):6291-9. doi: 10.1158/1078-0432.CCR-04-1850. Clin Cancer Res. 2005. PMID: 16144933
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Pellagatti A, Jädersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK, Merup M, Nilsson L, Samuelsson J, Sander B, Wainscoat JS, Boultwood J, Hellström-Lindberg E. Pellagatti A, et al. Among authors: samuelsson j. Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11406-11. doi: 10.1073/pnas.0610477104. Epub 2007 Jun 18. Proc Natl Acad Sci U S A. 2007. PMID: 17576924 Free PMC article.
The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.
Nilsson L, Edén P, Olsson E, Månsson R, Astrand-Grundström I, Strömbeck B, Theilgaard-Mönch K, Anderson K, Hast R, Hellström-Lindberg E, Samuelsson J, Bergh G, Nerlov C, Johansson B, Sigvardsson M, Borg A, Jacobsen SE. Nilsson L, et al. Among authors: samuelsson j. Blood. 2007 Oct 15;110(8):3005-14. doi: 10.1182/blood-2007-03-079368. Epub 2007 Jul 6. Blood. 2007. PMID: 17616640 Free article.
Constitutional inv(3) in myelodysplastic syndromes.
Gahrton C, Nahi H, Jansson M, Wallblom A, Alici E, Sutlu T, Samuelsson J, Gahrton G. Gahrton C, et al. Among authors: samuelsson j. Leuk Res. 2010 Dec;34(12):1627-9. doi: 10.1016/j.leukres.2010.05.014. Epub 2010 Jun 9. Leuk Res. 2010. PMID: 20542563
Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
Björkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR, Andreasson B, Birgegård G, Linder O, Malm C, Markevärn B, Nilsson L, Samuelsson J, Granath F, Landgren O. Björkholm M, et al. Among authors: samuelsson j. J Clin Oncol. 2011 Jun 10;29(17):2410-5. doi: 10.1200/JCO.2011.34.7542. Epub 2011 May 2. J Clin Oncol. 2011. PMID: 21537037 Free PMC article.
246 results